Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association
出版年份 2022 全文链接
标题
Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association
作者
关键词
-
出版物
Lancet Haematology
Volume 9, Issue 5, Pages e361-e373
出版商
Elsevier BV
发表日期
2022-04-26
DOI
10.1016/s2352-3026(22)00073-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach
- (2021) Sumit Bhatnagar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
- (2021) David A. Sallman et al. JOURNAL OF CLINICAL ONCOLOGY
- When azoles cannot be used: the clinical effectiveness of intermittent liposomal amphotericin prophylaxis in haematology patients
- (2021) R Batchelor et al. Open Forum Infectious Diseases
- Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia
- (2021) Caitlin R. Rausch et al. CANCER
- Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life
- (2021) Pierantonio Menna et al. CHEMOTHERAPY
- Risk factors for invasive fungal infection in 5‐azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome
- (2021) Amanda Tey et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975‐2016
- (2021) Denise Riedel Lewis et al. CANCER
- Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia
- (2021) Tamer A Othman et al. Future Oncology
- Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib
- (2021) Muneerah M. Aleissa et al. LEUKEMIA RESEARCH
- Invasive Fungal Disease in Patients with Newly Diagnosed Acute Myeloid Leukemia
- (2021) Anastasia I. Wasylyshyn et al. Journal of Fungi
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
- (2021) Martin Hoenigl et al. DRUGS
- Management of drug–drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs
- (2021) Roger J Brüggemann et al. Lancet Haematology
- Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
- (2021) Hagop Kantarjian et al. Lancet Haematology
- Risk of invasive fungal infections in patients with high‐risk MDS and AML receiving hypomethylating agents
- (2020) Gee Youn (Geeny) Kim et al. AMERICAN JOURNAL OF HEMATOLOGY
- Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study
- (2020) Prithviraj Bose et al. CLINICAL INFECTIOUS DISEASES
- Midostaurin improves quality of life and mediator–related symptoms in advanced systemic mastocytosis
- (2020) Karin Hartmann et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients
- (2020) Daniel R Reed et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
- (2020) Jannik Stemler et al. ANNALS OF HEMATOLOGY
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
- (2020) Eytan M. Stein et al. BLOOD
- Clinical efficiency of epigenetic drugs therapy in bone malignancies
- (2020) Filomena de Nigris et al. BONE
- The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent
- (2020) Michael Ozga et al. Clinical Lymphoma Myeloma & Leukemia
- Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
- (2020) Andrew H. Wei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Invasive Mold Infections in FLT3-Mutated Acute Myeloid Leukemia
- (2020) Pakpoom Phoompoung et al. Clinical Lymphoma Myeloma & Leukemia
- Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study
- (2019) Krzysztof Mądry et al. Clinical Lymphoma Myeloma & Leukemia
- Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects
- (2019) David Dai et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- How I treat acute myeloid leukemia in the era of new drugs
- (2019) Courtney D. DiNardo et al. BLOOD
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
- (2019) Gail J. Roboz et al. BLOOD
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
- (2019) J Peter Donnelly et al. CLINICAL INFECTIOUS DISEASES
- Azole antifungals and new targeted therapies for hematological malignancy
- (2019) Julian Lindsay et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
- (2018) A.J. Ullmann et al. CLINICAL MICROBIOLOGY AND INFECTION
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome
- (2018) Kynlon Phillips et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study
- (2017) Philipp Koehler et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Acute myeloid leukemia and the infectious diseases consultant
- (2017) Victor Mulanovich et al. LEUKEMIA & LYMPHOMA
- Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes
- (2017) Jason A. Trubiano et al. LEUKEMIA & LYMPHOMA
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen
- (2017) Alaa M. Ali et al. Cancer Medicine
- Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
- (2016) Helena Pomares et al. MYCOSES
- Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts
- (2015) Tapan M. Kadia et al. AMERICAN JOURNAL OF HEMATOLOGY
- Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study
- (2015) Roberta De Angelis et al. EUROPEAN JOURNAL OF CANCER
- Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
- (2013) Catherine Dutreix et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Patterns of Infection in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Receiving Azacitidine as Salvage Therapy. Implications for Primary Antifungal Prophylaxis
- (2013) Jose F. Falantes et al. Clinical Lymphoma Myeloma & Leukemia
- Antifungal pre-emptive strategy for high-risk neutropenic patients: why the story is still ongoing
- (2013) C. Cordonnier et al. CLINICAL MICROBIOLOGY AND INFECTION
- Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study
- (2012) Drorit Merkel et al. AMERICAN JOURNAL OF HEMATOLOGY
- GRADE guidelines: 3. Rating the quality of evidence
- (2011) Howard Balshem et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology
- (2010) Gordon H. Guyatt et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More